Subtype
Liver Carcinoma
CI-CAN-00001073Explore in graph →
783 active trials14 approved drugs17 evidence items
- NCIt
- C7927
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001073Explore in graph →
Clinical trials
3,370 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (387)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00604721 | Selumetinib in Treating Patients With Locally Advanced or Metastatic Liver Cancer | completed | Phase 2 | 19 | National Cancer Institute (NCI)NIH | 1 | May 28, 2014 | clinicaltrials |
| NCT02018757 | Safety and Efficacy of Arsenic Trioxide Contained in TACE in the Treatment of HCC(SEATH) | unknown | Phase 2 | 250 | First Hospital of China Medical UniversityOTHER | 1 | May 28, 2014 |
| clinicaltrials |
| NCT00639509 | IMC-A12 in Treating Patients With Advanced Liver Cancer | completed | Phase 2 | 24 | National Cancer Institute (NCI)NIH | 1 | May 23, 2014 | clinicaltrials |
| NCT00493428 | Treatment of Non-Metastatic Hepatocellular Carcinoma in Humans by Increasing Gabaergic Activity: A Pilot Study | withdrawn | Phase 2 | 0 | University of ManitobaOTHER | 1 | May 16, 2014 | clinicaltrials |
| NCT00023946 | BMS-247550 in Treating Patients With Liver or Gallbladder Cancer | terminated | Phase 2 | 50 | National Cancer Institute (NCI)NIH | 1 | May 14, 2014 | clinicaltrials |
| NCT00044512 | A Study to Estimate Safety and Efficacy of Sorafenib (BAY43-9006) in the Treatment of Hepatocellular Carcinoma | completed | Phase 2 | 137 | BayerINDUSTRY | 5 | Apr 16, 2014 | clinicaltrials |
| NCT01272557 | Sorafenib Plus Doxorubicin Versus Sorafenib Alone for the Treatment of Advanced Hepatocellular Carcinoma: a Randomized Phase II Trial(SoraDox) | unknown | Phase 2 | 170 | PD Dr. med. Matthias DollingerOTHER | 1 | Apr 1, 2014 | clinicaltrials |
| NCT00142428 | Cetuximab in Patients With Unresectable or Metastatic Hepatocellular Carcinoma | completed | Phase 2 | 30 | Massachusetts General HospitalOTHER | 1 | Mar 18, 2014 | clinicaltrials |
| NCT00142467 | Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Patients With Hepatocellular Carcinoma | completed | Phase 2 | 33 | Massachusetts General HospitalOTHER | 1 | Mar 18, 2014 | clinicaltrials |
| NCT00361309 | SU011248 in Advanced Hepatocellular Carcinoma | completed | Phase 2 | 34 | Massachusetts General HospitalOTHER | 1 | Mar 18, 2014 | clinicaltrials |
| NCT01116635 | Clinical Study Examining the Safety and Efficacy of Doxorubicin Drug Eluting Microspheres Transarterial Embolization in the Setting of Hepatocellular Carcinoma (HCC) | completed | Phase 1 / Phase 2 | 24 | University of British ColumbiaOTHER | 1 | Mar 17, 2014 | clinicaltrials |
| NCT01215565 | Study of Sunitinib in Patients With Advanced/Inoperable Fibrolamellar Carcinoma(Fibrolam) | terminated | Phase 2 | 4 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Mar 13, 2014 | clinicaltrials |
| NCT00943449 | 4SC-201 (Resminostat) and Sorafenib in Advanced Hepatocellular Carcinoma(Shelter) | completed | Phase 2 | 57 | 4SC AGINDUSTRY | 2 | Jan 16, 2014 | clinicaltrials |
| NCT01128803 | Immunotherapy of Hepatocellular Carcinoma by Induction of Anti-alpha Fetoprotein Response | terminated | Phase 1 / Phase 2 | 1 | Nantes University HospitalOTHER | 1 | Nov 7, 2013 | clinicaltrials |
| NCT01204177 | Assessing BAY86-9766 Plus Sorafenib for the Treatment of Liver Cancer.(BASIL) | completed | Phase 2 | 70 | BayerINDUSTRY | 4 | Sep 6, 2013 | clinicaltrials |
| NCT01934829 | Urea Cream Treatment Sorafenib-Associated HSFR in HCC | completed | Phase 2 | 871 | Chinese Anti-Cancer AssociationOTHER | 1 | Sep 4, 2013 | clinicaltrials |
| NCT00862082 | Randomized Phase 1/2 Open-Label Trial of PR104 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC) | terminated | Phase 1 / Phase 2 | 14 | Proacta, IncorporatedINDUSTRY | 4 | Aug 23, 2013 | clinicaltrials |
| NCT00328770 | De Novo Sirolimus-based Immunosuppression After Liver Transplantation for Hepatocellular Carcinoma | completed | Phase 2 / Phase 3 | 70 | University of AlbertaOTHER | 1 | Jun 24, 2013 | clinicaltrials |
| NCT00052364 | Oxaliplatin in Treating Patients With Liver Cancer | completed | Phase 2 | 32 | National Cancer Institute (NCI)NIH | 1 | Jun 18, 2013 | clinicaltrials |
| NCT00091182 | Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment | completed | Phase 2 | 180 | National Cancer Institute (NCI)NIH | 1 | Jun 5, 2013 | clinicaltrials |
| NCT00238394 | Cediranib Maleate in Treating Patients With Locally Advanced or Metastatic Liver Cancer | completed | Phase 2 | 44 | National Cancer Institute (NCI)NIH | 1 | Jun 5, 2013 | clinicaltrials |
| NCT01861912 | Arsenic Trioxide TACE and Intravenous Administration in Unresectable Hepatocellular Carcinoma(ACTION) | unknown | Phase 2 / Phase 3 | 258 | Guangdong Provincial People's HospitalOTHER | 0 | Jun 5, 2013 | clinicaltrials |
| NCT00033462 | Erlotinib in Treating Patients With Unresectable Liver, Bile Duct, or Gallbladder Cancer | completed | Phase 2 | 78 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00077441 | Bortezomib in Treating Patients With Hepatocellular Carcinoma (Liver Cancer) | completed | Phase 2 | 55 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT01858207 | Combine TACE and RFA Versus RFA Monotherapy in Unilobar HCC of 3.1 to 7 cm Patient | unknown | Phase 2 | 60 | Shi-Ming LinOTHER | 1 | May 23, 2013 | clinicaltrials |
| NCT00242502 | Efficacy and Safety Study of Bevacizumab and Erlotinib to Treat Primary Liver Cancer That Cannot be Removed By Surgery | completed | Phase 2 | 62 | M.D. Anderson Cancer CenterOTHER | 1 | May 6, 2013 | clinicaltrials |
| NCT01821482 | A Study of DC-CIK to Treat Hepatocellular Carcinoma | unknown | Phase 2 | 100 | Guangxi Medical UniversityOTHER | 1 | Apr 12, 2013 | clinicaltrials |
| NCT00405873 | Study to Evaluate Tumour Response in Cancer Patients With Advanced Hepatocellular Carcinoma (Liver Cancer) With AMT2003 | terminated | Phase 2 | 73 | Auron Healthcare GmbHINDUSTRY | 1 | Mar 20, 2013 | clinicaltrials |
| NCT00988741 | Trial of ARQ 197 in Patients With Unresectable Hepatocellular Carcinoma (HCC) Who Have Failed One Prior Systemic Therapy | completed | Phase 2 | 107 | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)INDUSTRY | 5 | Feb 28, 2013 | clinicaltrials |
| NCT00071994 | Gefitinib in Treating Patients With Advanced Unresectable Hepatocellular Carcinoma (Liver Cancer) | completed | Phase 2 | 59 | National Cancer Institute (NCI)NIH | 1 | Feb 27, 2013 | clinicaltrials |
| NCT01394497 | Use of N-Acetylcysteine During Liver Procurement | completed | Phase 2 | 140 | Azienda Ospedaliera di PadovaOTHER | 1 | Feb 18, 2013 | clinicaltrials |
| NCT00047333 | Erlotinib in Treating Patients With Liver Cancer That Cannot be Surgically Removed | terminated | Phase 2 | 80 | National Cancer Institute (NCI)NIH | 1 | Jan 23, 2013 | clinicaltrials |
| NCT00517920 | Phase 2 Study of ABT-869 in Advanced Hepatocellular Carcinoma (HCC) | completed | Phase 2 | 44 | AbbVie (prior sponsor, Abbott)INDUSTRY | 4 | Jan 4, 2013 | clinicaltrials |
| NCT01567930 | Temsirolimus as Second-line Therapy in HCC | unknown | Phase 2 | 25 | University of Tennessee Cancer InstituteOTHER | 1 | Dec 17, 2012 | clinicaltrials |
| NCT01392131 | Safety and Efficacy of Oncoxin in Hepatocellular Carcinoma (HCC) | unknown | Phase 1 / Phase 2 | 40 | Clinical Research Organization, Dhaka, BangladeshOTHER | 1 | Dec 12, 2012 | clinicaltrials |
| NCT00966251 | Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With Hepatocellular Carcinoma | terminated | Phase 1 / Phase 2 | 2 | CureTech LtdINDUSTRY | 1 | Oct 23, 2012 | clinicaltrials |
| NCT00843934 | Trial of Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma(ACE500) | unknown | Phase 2 / Phase 3 | 450 | Nihon UniversityOTHER | 1 | Oct 19, 2012 | clinicaltrials |
| NCT01655641 | Study of Tranexamic Acid for Reducing Blood Requirement in Patients Undergoing Major Gastro-intestinal Surgery(TMGS) | unknown | Phase 2 / Phase 3 | 118 | Tribhuvan University Teaching Hospital, Institute Of Medicine.OTHER | 1 | Oct 16, 2012 | clinicaltrials |
| NCT00614913 | Proton Beam Therapy for Treatment of Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 76 | Loma Linda UniversityOTHER | 1 | Aug 20, 2012 | clinicaltrials |
| NCT00080236 | Safety and Efficacy Study of a Caspase Inhibitor in Patients Undergoing Liver Transplantation | completed | Phase 2 | 99 | Conatus Pharmaceuticals Inc.INDUSTRY | 2 | Aug 10, 2012 | clinicaltrials |
| NCT00522405 | Randomized Control Trial (RCT) of Transarterial Chemoembolization (TACE) Versus TACE and Oral Drug Therapy in the Treatment of Unresectable Hepatocellular Carcinoma | unknown | Phase 2 / Phase 3 | — | All India Institute of Medical SciencesOTHER | 1 | Jul 16, 2012 | clinicaltrials |
| NCT01438450 | Oral Chemotherapy Versus Supportive Therapy In The Treatment Of Unresectable Hepatocellular Carcinoma(OTCHCC) | unknown | Phase 2 / Phase 3 | 74 | All India Institute of Medical SciencesOTHER | 1 | Jul 13, 2012 | clinicaltrials |
| NCT00731445 | Phase I/II Study of Z-208 in Advanced Hepatocellular Carcinoma (HCC) | completed | Phase 1 / Phase 2 | 43 | Zeria PharmaceuticalINDUSTRY | 1 | Jul 3, 2012 | clinicaltrials |
| NCT01008358 | Anti-CTLA-4 Human Monoclonal Antibody CP-675,206 in Patients With Advanced Hepatocellular Carcinoma | completed | Phase 2 | 20 | Clinica Universidad de Navarra, Universidad de NavarraOTHER | 1 | Jun 8, 2012 | clinicaltrials |
| NCT00618384 | TACE and Sorafenib for Advanced Hepatocellular Carcinoma (HCC)(SOCRATES) | terminated | Phase 2 | 43 | Heinrich-Heine University, DuesseldorfOTHER | 1 | Jun 7, 2012 | clinicaltrials |
| NCT00919009 | Combination of Transcatheter Arterial Chemoembolization (TACE) and Sorafenib for Patients With Unresectable Hepatocellular Carcinoma (HCC) | completed | Phase 2 | 50 | National Cancer Center, KoreaOTHER_GOV | 1 | May 30, 2012 | clinicaltrials |
| NCT01605734 | TACE Combinated With Sorafenib in Treating Patients With Unresectable Hepatocellular Carcinoma | unknown | Phase 2 | 120 | Shandong Cancer Hospital and InstituteOTHER | 1 | May 25, 2012 | clinicaltrials |
| NCT00867750 | SIR-Spheres® Microspheres Versus Transarterial Chemoembolisation in Patients With Unresectable Hepatocellular Carcinoma(SIRTACE) | completed | Phase 2 | 28 | Sirtex MedicalINDUSTRY | 2 | May 7, 2012 | clinicaltrials |
| NCT00775073 | Antiangiogenic Treatment of Hepatocellular Cancer With Bevacizumab and RAD001 | completed | Phase 2 | 33 | Gerhard TreiberINDIV | 1 | Apr 30, 2012 | clinicaltrials |
| NCT01556815 | Sorafenib Combined With Transarterial Chemoembolization in Treating HBV-infected Patients With Intermediate Hepatocellular Carcinoma | unknown | Phase 2 | 40 | Shandong Cancer Hospital and InstituteOTHER | 1 | Apr 25, 2012 | clinicaltrials |
Data updated 23 days agoSource updated May 28, 2014source: clinicaltrials